The aim of this systematic review was to capture the current knowledge regarding the adverse events, the complications and the unfavorable structural and functional outcomes of intravitreal anti-VEGF agents and LPC as treatment modalities for TR-ROP, so as to guide clinical ophthalmologists in their choice of the preferred treatment modality for each case of TR-ROP. Here, VEGFA is linked to retinopathy of prematurity.